Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... Real-world evidence has shown that treatment with the newer SGLT2 inhibitor class of diabetes drug

Latest news

  • Merck & Co and Pfizer take aim at diabetes with trio of new drugs Merck & Co and Pfizer take aim at diabetes with trio of new drugs

    Merck (known as MSD outside North America) and Pfizer have been working together on ertugliflozin's development since 2013, but are late to the SGLT2 inhibitor party as there are already ... The first SGLT2 inhibitor to be approved in the US was Johnson

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The FDA turned down Qtern with a request for more data 16 months ago,

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    waited for data from a cardiovascular outcomes trial involving rival SGLT2 inhibitor Invokana (canagliflozin) from Johnson &Johnson, due to report next year. ... Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin)

  • AstraZeneca's Forxiga set to be recommended by NICE AstraZeneca's Forxiga set to be recommended by NICE

    Currently in the final stages of consultation, the guidance endorses the use of AstraZeneca's SGLT2 inhibitor Forxiga (dapagliflozin) in patients already taking two drugs for blood sugar control without success. ... It has since been backed as a

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    SGLT2 inhibitor Forxiga (dapagliflozin) is one of AZ's fastest-growing products, with sales rising nearly 90% to $376m in the first half of the year. ... It is however facing intense competition from Boehringer Ingelheim and Eli Lilly's rival SGLT2

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics